OGI Investigators participated in 10th annual Retinal Therapy Innovation Summitt

June 17, 2025

The Retinal Therapy Innovation Summitt brings together scientists seeking the latest news on emerging therapies for Inherited Retinal Disorders

Jason Comander, MD, PhD, shared results from his project that used high-throughput screening of all variants in RHO to identify all the mutations that lead to protein misfolding. This information will help the company Octant which is developing OCT-980, a molecule to treat RHO protein misfolding. The company is planning to launch a clinical trial for OCT-980 in early 2026.

The Regulatory Endpoints and Trial Design for IRDs (REDI) Working Group is, a project organized by the Foundation’s Clinical Consortium and led by Rachel Huckfeldt, MD, PhD. Dr. Jacque Duncan reported on how The REDI Working Group is using data from natural history studies to develop and compare new candidate endpoints for clinical trials of IRD therapies – endpoints that can potentially be validated by the FDA and other regulators.